Nanoviricides, Inc. financial data

Symbol
NNVC on NYSE
Industry
Pharmaceutical Preparations
Location
1 Controls Drive, Shelton, CT
State of incorporation
NV
Fiscal year end
June 30
Latest financial report
10-K - Q2 2024 - Sep 27, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 514 % -77.7%
Debt-to-equity 11.7 %
Return On Equity -69.8 % -51.4%
Return On Assets -62.5 % -41.7%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 14.7M shares +25%
Common Stock, Shares, Outstanding 13.1M shares +12.4%
Entity Public Float 11.4M USD -7.2%
Common Stock, Value, Issued 131 USD +12%
Weighted Average Number of Shares Outstanding, Basic 11.9M shares +2.11%
Weighted Average Number of Shares Outstanding, Diluted 11.9M shares +2.11%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 5.44M USD -14.9%
General and Administrative Expense 3.08M USD +20.7%
Operating Income (Loss) -8.52M USD +4.78%
Nonoperating Income (Expense) 222K USD -37.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -1.97M USD -25.3%
Net Income (Loss) Attributable to Parent -8.29M USD +3.43%
Earnings Per Share, Basic -0.7 USD/shares +5.41%
Earnings Per Share, Diluted -0.7 USD/shares +5.41%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 4.8M USD -41.1%
Assets, Current 4.97M USD -41.1%
Property, Plant and Equipment, Net 7.51M USD -7.33%
Intangible Assets, Net (Excluding Goodwill) 325K USD -2.48%
Assets 12.8M USD -24.1%
Employee-related Liabilities, Current 23.5K USD -39.8%
Accrued Liabilities, Current 262K USD +82.6%
Liabilities, Current 1.36M USD +154%
Liabilities 1.36M USD -33.2%
Retained Earnings (Accumulated Deficit) -139M USD -6.33%
Stockholders' Equity Attributable to Parent 11.5M USD -22.9%
Liabilities and Equity 12.8M USD -24.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.17M USD -13.4%
Net Cash Provided by (Used in) Financing Activities -71K USD +0.54%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 13.1M shares +12.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 4.8M USD -41.1%
Interest Paid, Excluding Capitalized Interest, Operating Activities 0 USD -100%
Deferred Tax Assets, Valuation Allowance 39.8M USD +6.37%
Deferred Tax Assets, Gross 39.8M USD +6.37%
Depreciation 751K USD +1.55%
Payments to Acquire Property, Plant, and Equipment 8.29K USD -81.4%
Property, Plant and Equipment, Gross 15M USD +1.06%
Deferred Tax Assets, Operating Loss Carryforwards 29.4M USD +4.98%
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 151M USD +3.35%
Amortization of Intangible Assets 2.07K USD 0%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 13.3K USD